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Background: Interleukin (IL)-22 is a critical mediator of mucosal immunity and tissue regeneration, protecting against a number of respiratory
pathogens. Whether IL-22 confers protection against chronic Pseudomonas aeruginosa (PA) infection in cystic ﬁbrosis (CF) is unknown.
Methods: Explanted CF lungs were examined for IL-22 production and immune-localization. A murine model of persistent pulmonary PA
infection was used to examine production of IL-22 following infective challenge. The role of IL-22 was examined using IL-22 knockout (KO)
animals.
Results: IL-22 is produced within the adult CF lung and localizes to the airway epithelium. IL-22 is produced by murine pulmonary lymph node
cells following lung infection. The absence of IL-22 resulted in no signiﬁcant difference in acute mortality, bacterial burden, chronic infection
rates, histological changes or neutrophilic inﬂammation in the chronic PA infection model. However, IL-22 KO animals lost less weight following
infection.
Conclusion: IL-22 is produced in the CF lung and in response to PA infection yet is dispensable in protection against chronic pulmonary
P. aeruginosa infection in a murine model. However, we identiﬁed a novel role for the cytokine in promoting infection-related weight-loss, a
signiﬁcant prognostic factor in the CF population.
© 2016 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).Keywords: Cystic ﬁbrosis; Pseudomonas aeruginosa; Chronic infection; Interleukin-22; Mucosal immunity1. Introduction
Pseudomonas aeruginosa (PA) remains an important
pathogen in cystic fibrosis (CF) with its extensive armament
of virulence factors and evolving resistance profile [1,2].
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(2016), http://dx.doi.org/10.1016/j.jcf.2016.06.008urinemajority of patients and result in poorer lung function and
patient survival [1–3]. Current treatment strategies can delay
onset of such chronic airways infection, but truly preventative
measures, including anti-pseudomonal vaccines [4], remain
elusive. Thus, identifying a critical anti-pseudomonal host
response could enable therapeutic immunomodulation.
Interleukin-22 (IL-22), a member of the IL-10 family of
cytokines, has recently attracted attention as a critical mediator of
mucosal host defense, including the lung [5,6]. IL-22 is produced
by T helper (Th) 17 cells, Th22 cells, γδ T cells, natural killer
(NK) T cells and innate lymphoid cells (ILCs) [5,6]. Via itsmodel of chronic pulmonary Pseudomonas aeruginosa infection, J Cyst Fibros
2 H.K. Bayes et al. / Journal of Cystic Fibrosis xx (2016) xxx–xxxactions on non-haemopoieitic cells, IL-22 predominantly func-
tions in tissue protection and repair—increasing innate defenses
via expression of β-defensins, S100 proteins and lipocalin-2,
maintaining transepithelial barrier functions and enhancing
tissue regeneration [6]; thus representing an attractive therapeutic
target. However, IL-22 may also exacerbate pro-inflammatory
tissue-damaging responses in the lung when acting in synergy
with the pro-inflammatory cytokine IL-17 [5,7].
In respiratory infections, IL-22 provides critical immunity
against Klebsiella pneumoniae [8], Streptococcus pneumoniae
[9], Chlamydia muridarum [10], influenza [11,12], as well as
the CF pathogen Aspergillus fumigatus [13]. A protective role
of IL-22 against pulmonary P. aeruginosa infection potentially
exists [14,15], but is yet to be clearly defined.
Interleukin-22 production is evident in patients with CF and
pseudomonas infection. We have demonstrated that CF patients
have peripheral Pseudomonas-specific Th22 and Th17 cells
which may produce IL-22 in an antigen-specific manner and
home to the infected lung [16]. In addition, explanted pulmonary
lymph nodes of CF patients contain CD4+ IL-22+ T cells specific
for P. aeruginosa antigens [17]. IL-22 transcript expression has
also been found to be increased in lung tissue [17] as well as
IL-22 levels in sputum and plasma [18] of CF patients.
We examine explanted CF lung airway IL-22 expression and
IL-22 immune localization to further demonstrate cytokine
involvement in the CF lung environment. To define the role of
IL-22 in immunity to chronic P. aeruginosa infection, we utilized
the agar beadmodel of persistent pulmonary infection [19] in mice,
determining whether the cytokine is produced in response to
infection and its role in determining acute outcome, chronic
infection, inflammatory response, and infection-relatedweight loss.
2. Methods
2.1. Ethics
Approval was obtained from the Newcastle and North
Tyneside 2 Research Ethics Committee (07/Q0906/47). In-
formed consent was obtained from all participants at the time of
acceptance onto the active lung transplantation list at the
Freeman Hospital, Newcastle Upon Tyne, UK. Characteristics
of the 14 patients in the study who underwent lung trans-
plantation for end-stage CF are contained in Supplementary
Table 1.
2.2. Airway lavage samples
Airway lavage fluid was obtained from the explanted lungs
of CF patients undergoing lung transplantation, as previously
described [20].
IL-22 levels were measured via ELISA (eBioscience) with a
lower limit of detection of 2 pg/mL.
2.3. Immunohistochemistry
Airway blocks were dissected to provide intermediate/large
airways of 1–5 mm diameter with intact columnar airwayPlease cite this article as: Bayes HK, et al, IL-22 exacerbates weight loss in a murine
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sectioned at 5 μm and stained with haematoxylin and eosin to
check for the presence of appropriate airway epithelia.
Sections for IL-22 staining were de-waxed in xylene and
rehydrated through graded alcohols. Endogenous peroxidase
activity was blocked by soaking sections in 0.3% methanolic
hydrogen peroxide. The sections were washed for 10 min in
running tap water and rinsed in tris-buffered saline (TBS).
Antigen retrieval was performed in tris-EDTA-Triton X buffer
at pH 9 (10 mM tris, 1 mM EDTA, 0.02% Triton X-100) at
boiling point for 10 min. The sections were then allowed to
cool for 20 min before blocking with 5% non-fat milk protein
in TBS for 10 min. The primary antibody was a rabbit
polyclonal immunoglobulin anti-IL-22 (Millipore, reference
06-1076) diluted 1:100 in 3% bovine serum albumin and
applied for 24 h in a bioassay incubating tray at 4 °C.
Sections were washed twice with TBS and treated with a
biotinylated horse anti-rabbit Envision secondary antibody
system (Dako Laboratories) for 30 min. Sections were washed
twice with TBS and treated with the ABC Vectastain Elite kit
and DAB as per the manufacturer's instructions. The sections
were finally counterstained with Carazzi's stain for 1 min and
mounted. Negative controls were performed by omission of the
primary antibody and treatment with isotype normal rabbit
immunoglobulin (Dako Laboratories).2.4. Agar bead infection model
The infection model was adapted from the protocol
described by van Heeckeren et al. [19] and is widely utilized
in CF research with inflammatory, microbial and remodeling
akin to human CF lung disease [21,22]. Wild-type (WT)
mice were inoculated with sterile agar beads compared with
P. aeruginosa-laden beads. In separate experiments examining
the effect of IL-22, both WT and IL-22 knockout (IL-22 KO)
mice were infected with PA-laden agar beads.
P. aeruginosa-laden agar beads were prepared the day
before inoculation, stored overnight at 4 °C, and a different
bead preparation used for each experiment. PA-laden beads
were stored on ice throughout the murine surgery. Following
inoculation of PA-laden beads, the administrated inoculum was
confirmed by homogenization and quantitative bacteriology.
Sterile agar beads were stored at 4 °C, used for several
experiments and confirmed as sterile before and after each use.
For inoculation of beads, mice were anaesthetized using
isofluorane via nose cone and the trachea exposed and
cannulated (22G intravenous cannulae; BD Biosciences)
under aseptic conditions. WT mice were infected at inoculum
1 × 106 CFU per animal for comparison of response against
sterile bead-treated animals. An initial low-dose experiment, of
1 × 105 CFU/50 μl per animal, was undertaken to judge
potential toxicity in genetically modified animals, followed by
three subsequent experiments utilizing 1 × 106 CFU/50 μl per
animal. Daily weights were used as a measure of disease
progression and those with weight loss of greater than 20% of
baseline weight were culled prior to the predefined experimentmodel of chronic pulmonary Pseudomonas aeruginosa infection, J Cyst Fibros
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inoculation via carbon dioxide asphyxiation.
Bronchoalveolar lavage (BAL), pulmonary lymph nodes
and lung tissue were harvested under aseptic conditions. A total
of 1 ml of sterile phosphate-buffered saline (PBS) was infused
and aspirated into the airways three times for each BAL sample.
Thoracic lymph node cells were obtained from the bilateral
mediastinal lymph nodes and single tracheobronchial lymph
node [23].
2.5. P. aeruginosa strains
The clinical NH57388A strain was provided by N. Hoffmann
(University of Copenhagen), the strain possesses a mutation in
mucA resulting in alginate hyper-production [24]. The mucoid
YH5 strain and non-mucoid GRI-1 strains were obtained locally,
from a patient with CF and with ventilator-associated pneumonia,
respectively. PA strains were maintained in −80 °C stocks until
required. Both the NH57388A and YH5 strains were used to
form PA-laden agar beads as described previously [19]. For
production of heat-killed PA, each strain was grown to mid-log
phase in Luria–Bertani (LB) broth (Invitrogen) and the bacterial
concentration at OD600 readings between 0.4 and 0.6 were
quantified by serial dilution and plating to enumerate colony-
forming units (CFU) (GeneQuant Pro spectrophotometer,
Amersham Biosciences). PA were heated at a known concentra-
tion in PBS to 95 °C for 10 min.
2.6. Animals
All mice were used between 12 and 16 weeks of age. IL-22
KO mice were supplied by Genentech [25]. All murine lines
had a C57BL/6 background. C57BL/6 mice bred in-house were
used as wild-type controls for knockout comparisons. Animal
work was carried out under a Project Licence as required by
UK Home Office regulations as well as scrutiny and approval
by an Institutional Review board at the University of Glasgow.
2.7. Bacteriology
Lung tissue wasmechanically homogenized in 1 ml PBS. BAL
and lung homogenates were plated for quantitative bacteriology on
LB agar and examined after 24 and 48 h of incubation. Colonies
were confirmed to be PA by appearance, Gram stain (BD
Biosciences) and oxidase testing (Sigma-Aldrich). Chronic
infection was defined as recovery of mucoid PA from lung
cultures at 2 weeks post-inoculation. Pulmonary bacterial burden
was calculated from BAL and right lung homogenates.
2.8. Neutrophil quantification
Blood and BAL samples underwent red blood cell (RBC)
lysis (red cell lysis buffer; Sigma-Aldrich) prior to staining with
Gr-1 (Ly6G; RB6-8C5; BioLegend). CountBright Absolute
Counting Beads (Invitrogen) were added prior to washing cells
and used according to the manufacturer's instructions. StainedPlease cite this article as: Bayes HK, et al, IL-22 exacerbates weight loss in a murine
(2016), http://dx.doi.org/10.1016/j.jcf.2016.06.008cells were analyzed using FACs Aria (BD Biosciences) and
FlowJo software (Treestar).2.9. Cytokine measurement
Murine IL-17A, IL-17F, IL-21, interferon-γ (IFN-γ), and
IL-22 were quantified by ELISA (all eBioscience). Lower limits
of detection were: IL-17A b 4 pg/ml, IL-17F b 15 pg/ml,
IL-21 b 16 pg/ml, IFN-γ b 15 pg/ml and IL-22 b 8 pg/mL.
Cytokine levels less than the lower limits of detection of the
assay were assigned a value of zero.2.10. Histology scoring
Inflation fixed murine lungs were embedded in paraffin,
sectioned at 5 μm and stained with haematoxylin and eosin.
Histology was scored for peribronchial and alveolar involve-
ment using a scoring system adapted from that described by
Dubin et al. [15]. Scoring of each lung section was performed
blindly at ×10 magnification by two independent investigators
with an overall score given following assessment of a randomly
selected whole lung section.2.11. Mediastinal lymph node stimulation
Mediastinal lymph nodes were passed through 80 μm nitex
mesh and RBCs lysed to form a single cell suspension. Cells
were either left unstimulated or stimulated with heat-killed PA
at MOI30. Following 3 days of culture, 100 μl of supernatant
was removed for cytokine quantification.2.12. Statistics
Results are presented as medians or, for technical repeats,
mean and standard error of the mean (SEM). Mann–Whitney
test was used for non-parametric comparisons. For parametric
testing, Student's 2-sample t-test was used. Proportions were
compared via Fishers' exact test. Comparison of animal weight
changes were analysed using a repeated-measures ANOVA.
Survival data was analysed via log-rank (Mantel–Cox) test.
Statistical analysis was undertaken using Prism Version 6.0
(GraphPad Software). A p-value of b0.05 was considered
significant.3. Results
3.1. IL-22 production and airway epithelial localization in
explanted CF lung
IL-22 was evident in airway lavage obtained from the
explanted lungs of adult patients with CF undergoing transplan-
tation (Fig. 1a). IL-22 was identified, via immunohistochemistry
of explanted CF lung tissue, to localize to the airway epithelium
with more sparse staining in lung parenchyma (Fig. 1b).model of chronic pulmonary Pseudomonas aeruginosa infection, J Cyst Fibros
Fig. 1. IL-22 responses in explanted human CF lung and murine persistent pulmonary Pseudomonas aeruginosa infection. (a) IL-22 levels were measured in airway
lavage fluid from explanted lungs of CF patients undergoing lung transplantation. (b) Representative immunohistochemistry staining for IL-22 in the lower airway
epithelium of an explanted lung from a person with CF undergoing transplantation, and (c) demonstrating corresponding isotype control (both ×20 magnification).
(d-e) C57Bl6 mice were treated with intrapulmonary sterile agar beads or agar beads laden with P. aeruginosa, strain NH57388A. Lung homogenate (d) IL-22 levels
measured at 2 weeks post-instillation. Data representative of 3 separate experiments. P-value related to Mann–Whitney test. (e) Two weeks after infection,
mediastinal lymph node cells from mice treated as shown were stimulated ex vivo with heat-killed PA strains (NH57388A, denoted as NH, and GRI-1) at MOI 30 or
left unstimulated (Un) for 3 days. Levels of IL-22 secretion are shown; bars are means and error bars are SEM. Un, unstimulated. NH, NH57388A. **** denotes
p b 0.0001, comparison with corresponding sterile bead group via unpaired t-test. Representative of results from three separate experiments.
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following infection
Comparison of animals treated with sterile or PA-laden agar
beads demonstrated no significant difference detectable in
IL-22 levels in BAL or lung homogenates at either 48 h (data not
shown) or 2 weeks (Fig. 1d) post-instillation. In addition, there
was no significant difference between infected animals and sterile
bead controls in other pulmonary cytokine levels related to Th17
cells, i.e. IL-17A, IL-17F, and IL-21 (Supplementary Fig. 1). No
detectable IL-17A or IL-22 was found in the BAL of treatment-
naïve wild-type mice.
We thus sought to ascertain if PA-specific immune responses
had been induced by the persistent pulmonary PA infection and
were able to produce IL-22 in an antigen-specific manner. Two
weeks following PA infection, there was a marked enlargement
of the mediastinal lymph nodes compared to control animals
(3.56 × 106 cells mean value for NH57388A-infected animals
versus 2.83 × 105 cells mean value for sterile bead-treated
animals; three separate experiments, p b 0.05). Ex vivo restim-
ulation of these lymph node cells from infected animals with
heat-killed bacteria of the infecting strain NH73788A or anPlease cite this article as: Bayes HK, et al, IL-22 exacerbates weight loss in a murine
(2016), http://dx.doi.org/10.1016/j.jcf.2016.06.008unrelated clinical PA strain GRI-1 for 3 days resulted in robust
production of IL-22, which was not evident in animals receiving
sterile beads (Fig. 1e). Similarly P. aeruginosa-specific produc-
tion of IL-17A by infected animals was evident (data not shown).
This suggests that IL-22 production can occur as a specific
response to pulmonary Pseudomonas infection and that there is
migration to and/or expansion of PA-specific IL-22+ producing
cells within the thoracic lymph nodes in response to pulmonary
infection.
3.3. IL-22 absence does not alter acute responses to pulmonary
PA infection
Having demonstrated that IL-22 could be produced locally
in response to pulmonary P. aeruginosa infection, we
compared the response to infection in wild-type mice and
animals lacking the ability to produce IL-22. The response was
assessed to two clinical mucoid strains of PA, NH57388A and
YH5, including at low- and high-inoculation dose in the latter.
To ensure IL-22 KO animals did not have altered responses to
the agar beads per se, we examined the impact of sterile agar
beads in IL-22 KO and WT mice at 48-h post-bead instillation.model of chronic pulmonary Pseudomonas aeruginosa infection, J Cyst Fibros
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score, microbiology (no organisms isolated) or blood and BAL
neutrophil levels between IL-22 KO and WT animals treated
with sterile beads (data not shown).
IL-22 has previously been shown to play a critical role in
protection from acute pulmonary infection with another
Gram-negative organism by maintaining transepithelial resis-
tance and preventing systemic spread [8,13]. In contrast, there
was no significant difference in acute mortality (i.e. prior to
pre-defined experimental endpoint) in any of the experiments
comparing persistent PA infection in IL-22 knockout and WT
animals. Higher rates of acute mortality in WT and IL-22 KO
groups were seen to the NH57388A strain compared with YH5
stain. Combined, there were a total of 7 acute deaths from 40
treated animals (17.5%) in both the presence and absence of
IL-22. In both WT and IL-22 KO groups, early termination was
due to weight loss greater than 20% of baseline and occurred
over the same time period of 3–5 days post-inoculation
(Fig. 2a). There was also no significant difference in bacterial
burden (Fig. 2b) nor in the level of acute inflammation, measured
via BAL leukocyte and neutrophil levels (Fig. 2c and d) in the
lungs of IL-22 KO compared with WT animals culled at these
early time-points (i.e. 3-5 days post-infection). Importantly, dueFig. 2. Acute response to pulmonary Pseudomonas aeruginosa infection with strain
(N = 10) and wild type (WT) (N = 10) mice received agar beads laden with PA stra
relates to comparison via log-rank (Mantel–Cox) test. In animals succumbing prio
pulmonary PA bacterial burden was measured on total lung homogenates and broncho
by flow cytometry at the time of termination. c, absolute BAL total alive leukocyte an
the median and p-values relate to Mann–Whitney test.
Please cite this article as: Bayes HK, et al, IL-22 exacerbates weight loss in a murine
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bacterial growth on terminal blood cultures of any animal at any
time-point. Thus, acute resistance to pulmonary PA infection was
unaltered in the absence of IL-22.3.4. IL-22 signaling does not provide resistance to chronic
pulmonary PA infection
At two weeks post-inoculation, there was no significant
difference in chronic pulmonary P. aeruginosa infection rates
between inoculated IL-22 KO and WT animals in any
experiment. At low inoculum YH5 infection, 37.8% (3/8)
WT compared with 14.3% (1/7) IL-22 knockouts were
chronically infected (p = 0.5962, Fishers' exact test). In the
high inoculum experiments, chronic infection was seen in 25%
(5/20 animals) in both WT and IL-22 KO groups. Pulmonary
bacterial burden in chronically infected animals was also
similar in IL-22 knockout (median 845 CFU, IQR: 505–1468)
and wild-type (median 380, IQR: 505–1468) animals (p =
0.9497, Fig. 3a). Thus, IL-22 does not provide critical
protection against the development of persistent pulmonary
PA infection.NH57388A in IL-22 knockout and wild-type mice. IL-22 knockout (IL-22 KO)
in NH57388A. a, Survival comparison between the two murine strains; p-value
r to termination of the experiment (early deaths; i.e. 3–5 days post-infection),
alveolar lavage (BAL) (b). c,d, BAL leukocytes were strained for Gr-1 followed
d neutrophil counts. d, percentage BAL neutrophil counts. In b–d, line indicates
model of chronic pulmonary Pseudomonas aeruginosa infection, J Cyst Fibros
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chronic PA infection
The absence of IL-22 signaling did not influence the level of
chronic inflammation measured by neutrophil levels both in
peripheral blood (Fig. 3b) and BAL (Fig. 3c and d). Total
leukocytes were marginally less in IL-22 KO BAL (Fig. 3c) but
there was no significant difference both for all animals
inoculated with PA-laden agar beads (Fig. 3b–d) and for
those remaining chronically infected (data not shown) in
neutrophilic inflammation.
Persistent pulmonary inflammatory changes were evident
2 weeks post-inoculation of PA-laden agar beads (Fig. 3d-i).
Minimal changes were seen in response to sterile agar bead
instillation per se (Fig. 3e). Infected lungs demonstrated
localized peribronchial monocytic infiltrates with an agar
bead frequently evident in the adjacent airway (Fig. 3f) and
higher histological score in WT animals treated with PA-laden
compared with sterile agar beads (Fig. 3i). Histological
changes were similar in WT (Fig. 3g) and IL-22 KO (Fig. 3h)
mice treated with PA-laden agar beads, with no significant
difference in lung histological scores at 2 weeks post-
inoculation (Fig. 3j).
3.6. Weight loss related to infection is attenuated by the
absence of IL-22
Post-procedure weight loss was significantly greater and
sustained in WT animals treated with PA-laden beads compared
with sterile bead controls (p b 0.0001, via repeated measures
ANOVA; data not shown). Interestingly, there was significantly
less weight loss in IL-22 knockout animals compared with WT
mice treated with PA-laden agar beads (Fig. 4). This lower level
of weight loss in the absence of IL-22 remained evident when
only chronically infected animals were compared (p b 0.0001,
via repeated measures ANOVA; Fig. 4b).
4. Discussion
Consistent with our previous work demonstrating
IL-22-producing P. aeruginosa-specific responses in the
peripheral blood of patients with CF [16], we demonstrate
airway IL-22 production and IL-22 localization to the airway
epithelium in explanted lung tissue from CF patients. In
addition, we demonstrate that murine persistent pulmonary PA
infection elicits an antigen-specific response able to produce
IL-22 locally in draining lymph nodes. We found no difference
in IL-22, and other related cytokines, in the lungs of animalsFig. 3. Bacterial burden and inflammatory response in IL-22 knockout and wild-typem
(IL-22 KO) and wild type (WT) mice received intra-pulmonary agar beads laden w
assessed at 2 weeks post-inoculation. (a) Pulmonary bacterial burden (CFU count, cal
Combined results for 3 experiments utilizing YH5 strain. (b-d), Blood (b) and BA
Representative of results for three separate experiments. (c) Absolute BAL total a
(e–h) H&E staining of representative lung sections (all at ×10 magnification) in WTm
agar beads in WT mice (f) and 2 weeks post-inoculation with YH5-laden agar beads i
airway. (i) Quantitative histological scores of WT animals treated with sterile agar bea
WT (N = 8) and IL-22 KO (N = 10) animals treated with YH5-laden agar beads. Lin
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(2016), http://dx.doi.org/10.1016/j.jcf.2016.06.008treated with PA compared with sterile bead-treated animals.
Trauma itself may induce cytokine production and thus the
observed lack of difference may be attributable to the mode of
bead inoculation.
Despite its reported protective role against a range of
pulmonary pathogens [8–12], we found no evidence that IL-22
is critical in preventing the establishment of chronic pulmonary
P. aeruginosa infection. The most striking effect of IL-22 was
in relation to infection-associated weight loss. Poor growth and
impaired nutritional status are now recognized as important
determinants of pulmonary health and survival in CF [3,26].
Determinants of low weight are likely multifactorial; however,
pulmonary PA infection and the associated inflammation
are important contributors [27]. Our model demonstrated
weight loss in relation to P. aeruginosa infection, which was
significantly less marked in the absence of IL-22 (Fig. 4). The
mechanism by which IL-22 causes weight loss in pulmonary
PA infection is not clear and may include multiple direct and
indirect effects of the cytokine. We found no difference in
bacterial burden or pulmonary inflammation levels in the
presence or absence of IL-22 that might explain the difference
between groups. There may yet be a pathological effect of
IL-22 in promoting systemic and airways inflammation,
perhaps regulated by IL-17 [7], which was undetected in the
present study but which exacerbates the weight loss associated
with infection. In addition, recent data suggests a new role for
IL-22 in regulating metabolic homeostasis including insulin
sensitivity [28] and production [29] as well as regulation of
lipid metabolism in liver and adipose [28]; with studies to-date
identifying complex and beneficial effects on metabolism in
murine models of obesity [28,29]. Thus, our observed increased
weight loss in the presence of IL-22 could also represent an
effect on metabolism independent of the cytokine's immune
function.
Interleukin-22 exerts an important role in maintaining
mucosal integrity with resultant prevention of systemic spread
of organisms [8]. Thus, importantly, we demonstrated IL-22
localization to the airway epithelium in human CF lung (Fig. 1),
which may represent production and/or binding of the
cytokine at this site of immune activity. However, akin to
P. aeruginosa infection in patients, the experimentally per-
sistent PA infection model demonstrates that intrabronchial
sepsis and transepithelial invasion is not a significant com-
ponent of pathogenesis. This may explain the lack of im-
portance of IL-22 in chronic pulmonary infection observed here
compared with the findings of others in acute lung infection
where transepithelial spread significantly influences disease
outcome [8,9,11,14].ice with chronic pulmonary Pseudomonas aeruginosa infection. IL-22 knockout
ith PA with pulmonary bacterial burden, neutrophil and histological response
culated from combination of bronchoalveolar lavage and right lung homogenate).
L (c,d) neutrophil levels, measured via straining for Gr-1 and flow cytometry.
live leukocyte and neutrophil counts. (d) Percentage BAL neutrophil counts.
ice with no treatment (healthy control); (e) 2 weeks post-inoculation with sterile
n WT (g) and IL-22 KO (h) mice. Small black arrow highlights agar bead within
ds (N = 9) or PA-laden agar beads (N = 9). (j) Quantitative histological scores of
e denotes median score. P-values relate to Mann–Whitney tests.
model of chronic pulmonary Pseudomonas aeruginosa infection, J Cyst Fibros
Fig. 4. Weight loss in wild-type and IL-22 knockout mice treated with Pseudomonas-laden agar beads. Body weight measured daily in wild-type (WT) and IL-22
knockout (IL-22 KO) mice treated with Pseudomonas aeruginosa-laden agar beads. Percentage weight change from baseline for pooled experiments. (a) All animals
infected with PA-laden beads (WT = 28, IL-22 KO = 27). (b) Only animals remaining chronically infected with PA at 2 weeks post-inoculation (WT = 8, IL-22
KO = 6). Each point represents mean of group and SEM. (a) Difference between groups significant at p b 0.0001 via repeated measures ANOVA. (b) Difference
between groups significant at p b 0.0001 via repeated measures ANOVA.
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homeostasis both in the lung and gut, and the inter-relationship
of gut and lung immunity is an area of growing interest. Shih et al.
demonstrate that mice lacking IL-22 and IL-22 neutralisation in
mice via exogenous anti-IL-22 antibody resulted in altered gut
microflora, with increased segmented filamentous bacteria (SFB)
that can promote Th17 cell development [30]. Gauguet et al.
demonstrated that the gut microbiome may influence pulmonary
immunity as mice with gut SFB showing increased BAL IL-22
levels and decreased susceptibility to acute S. aureus pneumonia
[31]. We did not examine the gut microflora of either the WT or
KO animals used in our research and whether the gut microbiome
has effects on persistent pulmonary infections is unexplored.
However, consideration of gut–lung interactions in the context of
CF would need to take account of the increasing evidence of
altered gut microbiota in CF patients [32,33].
A further function of IL-22 in mucosal immunity is in the
production of anti-microbial peptides including β-defensins and
S100 proteins [8]. Elevated levels of such anti-microbial proteins
have been demonstrated in the airway secretions of patients with
CF [34]. In addition, in the context of ocular infection, human
β-defensin 2 plays an important role in defense against P.
aeruginosa [35]. However, such anti-microbial factors may be
induced by alternative non-IL-22 pathways, including via IL-17
[36,37], and thus may further explain our observed lack of impact
of IL-22 on bacterial burden or infection rates in persistent PA
infection. Cross-talk between cytokines is undoubtedly important
in immunopathological outcomes [5,7] and thus dual manipulation
of IL-22 and IL-17 cytokines may provide further insights into the
important interactions within the complex cytokine milieu of the
infected CF lung.
Our infection model utilized PA-laden agar beads instilled
into animals with no previous lung infection. Interestingly,
Mear et al. found that prior Candida albicans lung infectionPlease cite this article as: Bayes HK, et al, IL-22 exacerbates weight loss in a murine
(2016), http://dx.doi.org/10.1016/j.jcf.2016.06.008resulted in IL-22 production from ILCs that provided cross-
protection against subsequent acute P. aeruginosa pneumonia
[14]. Similarly IL-22 was found to protect against superimposed
infection with S. pneumoniae following respiratory influenza A
infection [11]. Thus, assessing whether a similar IL-22 response
can be induced by an early CF pathogen, which provides cross-
protection against subsequent chronic mucoid PA infection, still
merits consideration.
Interleukin-22 functions in appropriate repair following
pulmonary insults. Simonian et al. used an experimental
model of pulmonary fibrosis, using repeated exposure to
Bacillus subtilis, demonstrating that IL-22 blockade results in
accelerated lung fibrosis [38]. A similar anti-fibrotic role for
IL-22 has been demonstrated following influenza infection with
a corresponding benefit in preserving lung function [12].
Whether IL-22 has a similar longer-term reparative role in the
CF lung is of interest but cannot be answered in the present
study. Our preliminary analysis of lung collagen deposition (via
Picro-sirius red collagen lung staining) in response to 2 weeks
of pulmonary PA infection suggested no difference between
wild-type and IL-22 KO animals (data not shown). Study of
more prolonged PA infection may reveal a role for IL-22 in
preventing aberrant lung repair and fibrosis.
Although interleukin-22 has attracted attention as a critical
mediator of mucosal immunity, we found no evidence that it
influences the short or longer-term outcome in experimental
chronic pulmonary P. aeruginosa infection. Critical to therapeu-
tic targeting and CF pathogenesis, IL-22 failed to protect against
the development of P. aeruginosa colonization. However, we
identified a novel role for IL-22 in exacerbating infection-induced
weight loss, an important prognostic factor in patients with cystic
fibrosis, which warrants further investigation.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2016.06.008.model of chronic pulmonary Pseudomonas aeruginosa infection, J Cyst Fibros
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